A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study-Reference-Cited by-同舟云学术

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study

Published:2020-12-11 Issue:1 Volume:35 Page:75-87
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Moorkens Evelien^ORCID,Vulto Arnold G.^ORCID,Kent James,McClure Lindsay,Boldero Richard,Vanhove Thibault,Simoens Steven^ORCID,Huys Isabelle^ORCID

Funder

University Medical Center Rotterdam

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-020-00456-5.pdf

Reference59 articles.

1. Download medicine data|European Medicines Agency: European Medicines Agency; 2020. https://www.ema.europa.eu/en/medicines/download-medicine-data. Accessed Aug 2020.

2. Commissioning framework for biological medicines (including biosimilar medicines): NHS England; 2017. https://www.england.nhs.uk/publication/commissioning-framework-for-biological-medicines/. Accessed Mar 2020.

3. Troein P, Newton M, Patel J, Scott K. The impact of biosimilar competition in Europe. IQVIA; 2019.

4. Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 1-biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285–97. https://doi.org/10.1007/s40259-019-00345-6.

5. Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 2-biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299–306. https://doi.org/10.1007/s40259-019-00346-5.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review;BioDrugs;2024-06-15

2. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly;BioDrugs;2024-06-11

3. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market;Expert Opinion on Biological Therapy;2024-06-06

4. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review;Frontiers in Public Health;2024-02-28

5. Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-10